cambridge's bluebird bio licenses delivery tech to novartis, gsk
.
.
.
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
.
.
.
senator: sir, i have the numbers in front of me. how can you keep this secret from the public?
.
.
.
.